drugset / Trial / NCT05737160
Study of Telitacicept in Generalized Myasthenia Gravis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
Timeline
- Start
- 2023-03-28
- Primary completion
- 2024-11-26
- Completion
- 2024-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |